|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
"""Social separation"" among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation."
|
16724273 |
2006 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations.
|
17452776 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tumors from BRCA1 mutation carriers are predominantly of basal subtype (i.e., triple negative), and BRCA2 mutation carriers are of luminal subtype (i.e., estrogen receptor positive).
|
17940826 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tumors (n = 3) from patients with a proven BRCA1 germline mutation also showed a significant relationship with numerical centrosome aberration (P = 0.011).
|
18813953 |
2009 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Mammary tumor development in dogs is associated with BRCA1 and BRCA2.
|
19887619 |
2009 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Breast tumors deficient in BRCA1 are mostly associated with basal-like breast cancers and targeted therapeutics for this disease subtype are still lacking.
|
29938573 |
2018 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tumours from BRCA1 and BRCA2 mutation carriers are genetically instable and display specific patterns of chromosomal aberrations, suggestive of distinct genetic pathways in tumour progression.
|
9467939 |
1998 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
BRCA1-regulated genes associated with breast tumorigenesis included the estrogen-responsive genes MYC and cyclin D1, which are overexpressed in many breast tumors; STAT1 and JAK1, key components of the cytokine signal transduction pathway; the extracellular matrix protein laminin 3A; ID4, an inhibitor of DNA-binding transcriptional activators, which in turn negatively regulates BRCA1 expression; and the prohormone stanniocalcin, expression of which is lost in breast tumor cells.
|
12032322 |
2002 |
|
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.
|
15868446 |
2005 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
BRCA1 protein was much less expressed in breast tumour tissue from patients with the 5' UTR mutation than in samples from patients without the mutation.
|
17697535 |
2007 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
BRCA1 protein was much less expressed in breast tumour tissue from patients with the 5' UTR mutation than in samples from patients without the mutation.
|
17697535 |
2007 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
|
18241344 |
2008 |
|
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
BRCA1 promoter methylation has also been observed in sporadic ovarian and breast tumors; however, BRCA2 promoter methylation has not been reported in sporadic tumors.
|
19340607 |
2009 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
BRCA1 is considered to be a tumor-suppressor gene, yet mutations in this gene are uncommon in sporadic breast tumors.
|
9639385 |
1998 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
BRCA1- and BRCA2-related breast tumors were distinct in their expression of steroid receptors.
|
9669814 |
1998 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
|
28825726 |
2017 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer.
|
11916966 |
2002 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
A protein truncating BRCA1 allele with a low penetrance of breast cancer.
|
15591272 |
2004 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A set of 16 miRNAs differentially expressed between BRCA 1/2-related and BRCAX breast tumors emerged from the profile analysis.
|
25333258 |
2015 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
|
12815598 |
2003 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A statistically significantly higher frequency of p53 mutations was found in breast tumors from carriers of BRCA1 mutations than from noncarriers, which adds to the accumulating evidence that loss of p53 function is an important step in the molecular pathogenesis of BRCA1 mutation-associated breast tumors.
|
10070948 |
1999 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
A total of 104 tumor tissue samples from 75 familial breast tumors (BRCA1, n = 14; BRCA2, n = 13; non-BRCA1/2, n = 48) and 29 sporadic tumors were analyzed.
|
24036693 |
2013 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Aberrant promoter hypermethylation of PALB2 is more frequent than the reported level of PALB2 point mutations in breast tumors from BRCA1/2-negative families and is similar to the frequency of BRCA1 hypermethylation in inherited and sporadic breast and ovarian cancers.
|
18281473 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Abnormalities in X chromosome copy number and in the epigenetic stability of the inactive X chromosome (Xi) have been proposed to characterize BRCA1 breast tumors.
|
17545591 |
2007 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Adjuvant systemic therapy for breast cancer in BRCA1BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
|
20135344 |
2010 |